We are pleased to announce the publication of our latest paper, “Evaluating the Efficacy of Monoclonal Antibodies Against a Bioactive Peptide Involved in Alzheimer’s Disease: A Methodological Approach.”
The paper outlines a methodological framework for assessing monoclonal antibodies targeting a bioactive peptide implicated in Alzheimer’s disease. This work contributes to the ongoing development of potential therapeutic approaches by supporting the careful evaluation of antibody candidates in preclinical research.
The publication reflects our continued commitment to advancing the understanding of Alzheimer’s disease and exploring innovative strategies that may help address its underlying biology.